Name | 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide |
---|---|
Synonyms |
[3H]-MK-0767
N-(4-trifluoromethylbenzyl)-5-(2,4-dioxothiazolidin-5-yl)methyl-2-methoxybenzamide [14C]-MK-0767 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide 5-(2,4-dioxothiazolidin-5-ylmethyl)-2-methoxy-N-[4-(trifluoromethyl)benzyl]benzamide MK 767 MK-0767 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide KRP 297 |
Description | KRP-297 is a PPARα and PPARγ agonist potentially for the treatment of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver. |
---|---|
Related Catalog | |
References |
Density | 1.395g/cm3 |
---|---|
Boiling Point | 605.4ºC at 760 mmHg |
Molecular Formula | C20H17F3N2O4S |
Molecular Weight | 438.42000 |
Flash Point | 319.9ºC |
Exact Mass | 438.08600 |
PSA | 116.78000 |
LogP | 4.38880 |
Vapour Pressure | 1.32E-14mmHg at 25°C |
Index of Refraction | 1.58 |